[Skip to Navigation]
Comment & Response
April 25, 2022

Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities

Author Affiliations
  • 1iCAB International Network, CAA and AD Translational Research Biomarkers, School of Medicine, University of Milano-Bicocca, Monza, Italy
  • 2Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany
  • 3Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
JAMA Neurol. 2022;79(6):633-634. doi:10.1001/jamaneurol.2022.0731

To the Editor Hall et al1 describe a patient with prodromal Alzheimer disease who developed 6 relapsing episodes of amyloid-related imaging abnormality edema (ARIA-E) over 44 months of treatment within the aducanumab long-term extension period. Together with the recently reported 41.3% risk of ARIA in the Phase 3 Study of Aducanumab in Early Alzheimer’s Disease (EMERGE and ENGAGE) trials,2 we believe this work is of particular interest as it points out ARIA as a timely research and clinical priority, prompting the urgent need to define standardized guidelines for the treatment and follow-up monitoring of such side events.

Add or change institution